CHF Solutions Protects New Peripheral Vascular Access Catheter with Patent Application
January 12 2021 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced the submission of a patent application for a peripheral
vascular access catheter for use with its Aquadex™ system. The new
dual lumen ultrafiltration catheter optimizes blood flow, prevents
kinking, and is customizable for each patient, eliminating the need
for multiple catheter sizes.
Ultrafiltration with Aquadex provides clinicians with a
simplified approach to gently remove excess fluid in patients with
hypervolemia (fluid overload). A key advantage of the Aquadex
system is its ability to provide venous access in the patient’s arm
rather than the common and less comfortable central vein access.
The addition of the innovative dual lumen catheter included in this
patent helps to streamline processes for uninterrupted therapy, and
may reduce inventory burden with the ability to customize a single
catheter to any patient.
“Blood flow optimization is an important element of effective
ultrafiltration therapy and the catheter designs in this patent
application will help elevate the precision clinicians have grown
to love with Aquadex,” said John Erb, CEO of CHF Solutions. “We’re
always looking for ways to improve each component of our therapy
and consistently equip providers with the tools they need to
provide the best care.”
Aquadex SmartFlow is a simple, flexible and smart fluid
management platform using ultrafiltration to stabilize patients
experiencing fluid overload. It can be used by any bedside nurse
trained on extracorporeal therapies and allows for up to a 4:1
patient to nurse ratio.
About CHF Solutions CHF
Solutions, Inc. (Nasdaq: CHFS) is a medical device company
dedicated to improving the lives of patients suffering from fluid
overload with its novel ultrafiltration therapy system. The company
is focused on developing, manufacturing and commercializing the
Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions
is headquartered in Minneapolis, Minn., with wholly-owned
subsidiaries in Australia and Ireland. The company has been listed
on the Nasdaq Capital Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the
product inventions contained in this patent application.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS
INVESTORS:Claudia Napal Drayton Chief Financial
Officer, CHF Solutions, Inc. 952-345-4205ir@chf-solutions.com
Matt Bacso, CFAGilmartin Group LLCMatt.bacso@gilmartinir.com
MEDIA:Jessica
StebingHealth+Commerce260-336-6202jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024